MedTrace Logo

SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors

NCT05354843 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2022-04-29

No results posted yet for this study

Summary

This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors. It is anticipated that approximately 37 subjects will be enrolled in the dose-escalation phase of the study. ET0038 will be administered orally once daily (QD) in 21-day treatment cycles.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

ET0038

ET0038 for oral administration

Sponsors & Collaborators

  • Etern BioPharma (Shanghai) Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Etern BioPharma (Shanghai) Co., Ltd · Etern BioPharma (Shanghai) Co., Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2023-10-01
Completion
2025-10-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354843 on ClinicalTrials.gov